Skip to content

Thoracic Tumours Register

Thoracic Tumours Register

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02941458
Acronym
RTT
Enrollment
10000
Registered
2016-10-21
Start date
2016-07-21
Completion date
2031-12-30
Last updated
2026-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic Tumors

Brief summary

Observational, multicenter study in patients with lung cancer and other thoracic tumors. The GECP, in its commitment to improve the treatment and prognosis of patients with lung cancer and other thoracic tumors, has marked the individualization of treatment according to the expression of markers predictive of response to chemotherapeutic agents and molecular inhibitors of cell proliferation as one of its primary objectives. This could significantly improve the prognosis of patients with lung cancer, and will lead to a radical change in routine clinical practice. The aim of the register is to explore all data available of all patients treated because of thoracic tumours.

Detailed description

Observational, multicenter study in patients with lung cancer and other thoracic tumors. In a prospective and retrospective way, information will be obtained from the clinical history of each patient. In Europe, patients with lung cancer have a poor prognosis, and there has been only limited improvement between 1999 and 2007. Potential advantages of the centralization of care and the discussion of treatment strategies in multidisciplinary teams, as suggested in other studies,13 require further research. However, the priorities should be to prevent lung cancer by implementing anti-smoking policies and controlling asbestos exposure throughout Europe, such as was recommended by the World Health Organization (WHO) in 2008.14 Other priorities are to reduce levels of residential radon in risk areas, and early diagnosis to improve the results of surgery, which is still the main curative treatment. The variability in the diagnostic process, treatment and advocacy, as well as the anticipated increase in associated mortality in Spain in coming years, has stimulated the creation of an epidemiological, observational, multicenter study of cases of lung cancer and other thoracic tumors diagnosed and treated by medical personnel, including both thoracic surgeons and medical oncologists. Data from this study will be collected retrospectively and prospectively, so as to enable an extensive study of the epidemiological and therapeutic factors related to the disease.

Interventions

None listed

Sponsors

Spanish Lung Cancer Group
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients with thoracic disease, treated with an active treatment or not treated (only palliative care)

Exclusion criteria

* Patients with other type of tumours

Design outcomes

Primary

MeasureTime frameDescription
Describe epidemiology characteristics of lung cancer and other thoracic tumors in Spanish peopleup to 10 yearsTo know the epidemiology characteristics of lung cancer and other thoracic tumors in Spain, as well as clinical and histological data, diagnosis, treatments received, and prognostic factors

Countries

Spain

Contacts

CONTACTEva Pereira
epereira@gecp.org+34934302006
PRINCIPAL_INVESTIGATORMariano Provencio, MD

Hospital Puerta del Hierro

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 24, 2026